Skip to main content
Assets
Tarsus Pharmaceuticals logo
TARS.NASDAQ
Tarsus Pharmaceuticals
Health Care · Pharmaceuticals

Biopharmaceutical company developing therapeutics for eye care, dermatology, and infectious disease conditions with unmet needs.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Tarsus Pharmaceuticals.

Historical AI ConsensusHistorical AI Opinions

Tarsus Pharmaceuticals Inc (TARS.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 July 2026Deep analysis 5 July 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts

1. Investment Thesis — Base Case

TARS is a Paradigm Shifter in category creation. The fundamental thesis is simple: the S-curve for XDEMVY is steep, the physics of lotilaner are proven, and the (93% ) are software-tier. At a ~$2.8B market cap, you are buying a hyper-growth cash cow for a fraction of its , while getting the TP-05 Lyme disease prophylactic and TP-04 Ocular Rosacea optionality entirely for free.

  • is imminent; TARS transitions to positive by H2 2026, rendering the Warsh cost-of-capital regime irrelevant.
  • XDEMVY's peak sales target of $2B is mathematically defensible given the 25M patient and rapid prescriber penetration.
  • Recent short-seller noise is a structural gift, artificially compressing the multiple precisely when operational derisking is peaking.
  • The pipeline recycles the same active ingredient, drastically reducing biological risk compared to standard biotech vaporware. The implied easily scales toward $10B as cash flow compounds and the platform expands.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.-17.9869.36156.71244.05331.39Jun 2021Dec 2023Jun 2026Dec 2028Jul 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2021-06-2930.0
Observed price2021-07-1925.6
Observed price2021-07-3122.5
Observed price2021-08-1226.3
Observed price2021-09-0526.1
Observed price2021-09-1722.8
Observed price2021-09-2921.5
Observed price2021-10-1528.5
Observed price2021-10-1928.9
Observed price2021-11-1227.2
Observed price2021-11-2427.7
Observed price2021-12-1023.7
Observed price2021-12-2225.8
Observed price2022-01-0722.8
Observed price2022-01-1122.5
Observed price2022-02-0417.55
Observed price2022-02-1214.81
Observed price2022-03-0419.09
Observed price2022-03-0819.40
Observed price2022-03-2817.00
Observed price2022-04-0517.60
Observed price2022-04-2519.08
Observed price2022-05-0711.13
Observed price2022-05-2714.36
Observed price2022-06-1212.76
Observed price2022-06-2415.35
Observed price2022-06-2814.00
Observed price2022-07-0615.48
Observed price2022-07-2614.91
Observed price2022-08-1518.39
Observed price2022-09-1216.48
Observed price2022-09-1614.80
Observed price2022-09-2416.08
Observed price2022-09-2817.79
Observed price2022-10-2216.04
Observed price2022-10-3018.52
Observed price2022-11-1517.80
Observed price2022-12-0915.48
Observed price2022-12-1315.17
Observed price2022-12-2514.36
Observed price2023-01-1814.54
Observed price2023-02-0316.26
Observed price2023-02-0715.66
Observed price2023-03-0314.96
Observed price2023-03-0715.16
Observed price2023-03-2312.14
Observed price2023-04-1212.00
Observed price2023-04-2814.92
Observed price2023-05-0214.52
Observed price2023-05-1016.70
Observed price2023-05-3015.76
Observed price2023-06-0719.11
Observed price2023-06-2717.01
Observed price2023-07-2124.6
Observed price2023-07-2922.6
Observed price2023-08-1416.83
Observed price2023-08-3017.49
Observed price2023-09-0715.50
Observed price2023-10-0518.52
Observed price2023-10-1312.98
Observed price2023-10-2113.09
Observed price2023-11-1017.47
Observed price2023-11-1818.41
Observed price2023-12-0416.42
Observed price2023-12-1218.02
Observed price2023-12-2820.7
Observed price2024-01-0920.5
Observed price2024-02-0228.5
Observed price2024-02-0629.6
Observed price2024-03-0137.0
Observed price2024-03-1730.9
Observed price2024-03-2936.2
Observed price2024-04-1035.9
Observed price2024-04-2632.0
Observed price2024-04-3031.4
Observed price2024-05-2038.7
Observed price2024-05-2834.4
Observed price2024-06-2126.1
Observed price2024-06-2525.8
Observed price2024-07-1129.9
Observed price2024-07-2327.8
Observed price2024-08-0421.6
Observed price2024-08-2426.2
Observed price2024-09-1333.3
Observed price2024-09-1731.1
Observed price2024-10-1135.7
Observed price2024-10-1936.6
Observed price2024-11-0849.4
Observed price2024-11-1644.8
Observed price2024-12-0651.8
Observed price2024-12-1050.6
Observed price2025-01-0355.7
Observed price2025-01-0755.1
Observed price2025-01-1546.6
Observed price2025-02-0454.5
Observed price2025-02-2844.5
Observed price2025-03-0444.5
Observed price2025-03-2452.4
Observed price2025-04-0945.9
Observed price2025-04-2550.0
Observed price2025-04-2950.9
Observed price2025-05-2343.0
Observed price2025-06-0843.4
Observed price2025-06-2040.6
Observed price2025-07-0640.2
Observed price2025-07-1843.3
Observed price2025-07-3040.0
Observed price2025-08-1554.2
Observed price2025-08-3158.6
Observed price2025-09-1249.4
Observed price2025-09-1650.6
Observed price2025-10-1070.1
Observed price2025-10-1872.4
Observed price2025-10-2667.5
Observed price2025-11-1573.3
Observed price2025-12-0581.8
Observed price2025-12-1777.8
Observed price2025-12-2582.1
Observed price2026-01-0679.9
Observed price2026-01-3064.5
Observed price2026-02-1561.8
Observed price2026-02-2775.5
Observed price2026-03-0376.5
Observed price2026-03-2364.1
Observed price2026-04-1272.6
Observed price2026-04-2461.5
Observed price2026-05-1060.2
Observed price2026-05-1465.2
Observed price2026-06-0358.8
Observed price2026-06-1963.3
Observed price2026-07-0566.6
Observed price2026-07-1359.3
Observed price2026-07-2157.3
Observed price2026-08-1469.2
Observed price2026-08-2670.7
Observed price2026-09-0788.1
Observed price2026-09-1578.2
Observed price2026-09-2374.3
Observed price2026-09-2575.7
Published advisor forecast2026-07-0265.4
Published advisor forecast2026-10-0275.3
Published advisor forecast2027-01-0282.8
Published advisor forecast2027-04-0292.7
Published advisor forecast2027-07-02109
Published advisor forecast2027-10-02118
Published advisor forecast2028-01-02130
Published advisor forecast2028-04-02136
Published advisor forecast2028-07-02146
Published advisor forecast2028-10-02139
Published advisor forecast2029-01-02153
Published advisor forecast2029-04-02165
Published advisor forecast2029-07-02185
Published advisor forecast2029-10-02194
Published advisor forecast2030-01-02209
Published advisor forecast2030-04-02222
Published advisor forecast2030-07-02244
Published advisor forecast2030-10-02254
Published advisor forecast2031-01-02269
Published advisor forecast2031-04-02283
Published advisor forecast2031-07-02302

2. Scenarios & Signals

Bull case

The Base Case materializes, and TP-05 completely reshapes infectious disease protocol.

  • TP-05 Calliope trial reads out highly positive, birthing a multi-billion dollar Lyme prophylactic market.
  • TARS transcends niche ophthalmology, becoming a systemic ectoparasiticide platform.
  • XDEMVY adoption accelerates globally, driving immense high-margin royalty streams from China and Europe.
  • Big Pharma capitulates to the 93% and acquires TARS at a massive premium, pushing valuation past $12B.

Bear case

The Base Case stalls due to exhaustion and pipeline failure.

  • XDEMVY adoption hits an asymptote early as the most severe patients are saturated.
  • SG&A costs spiral out of control to capture marginal prescribers, permanently destroying the narrative.
  • TP-05 fails in Phase 2, proving lotilaner cannot safely prevent Lyme in humans.
  • The company is trapped as a low-growth, single-asset grinder, bleeding multiple contraction in a high-rate regime.

Current crowd narrative

The crowd is currently distracted by a petty short report from Culper Research, sweating over 'valuation' and ' exhaustion' in a pre-profit biotech. Wall Street analysts lazily slap 'Strong Buy' labels based on standard DCF models but fundamentally miss the velocity of the S-curve. The media treats TARS as just another specialty pharma company playing in a niche eye-care sandbox, completely ignoring the structural platform optionality of lotilaner. The anchoring bias is tethered to standard biotech failure rates, ignoring that the active ingredient's physics are already derisked.

Alpha-gap assessment

The lies in the brutal physics of the and the predictability of this specific S-curve. TARS is trading at ~4x forward sales with 93% and +85% YoY growth. The crowd prices this as a one-trick pony with execution risk. The reality? XDEMVY is a category creator that has already achieved . Furthermore, the market assigns near-zero probability to the TP-05 Lyme disease prophylactic, fundamentally misunderstanding the biological crossover potential of the lotilaner platform.

Convergence catalyst

Convergence arrives within two quarters when Tarsus prints undeniable, sustainable positive , mathematically obliterating the short thesis. The secondary catalyst is the H1 2027 Calliope trial data for TP-05, forcing the market to price the massive Lyme disease into the baseline valuation.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus